In the early months of the COVID-19 pandemic, Africa’s rapid and coordinated response, informed by emerging data, was remarkable. Now, in 2022, as vast vaccination campaigns have enabled the global north to gain some control over the pandemic, Africa lags behind.
As Americans celebrated Thanksgiving this year, the news broke that South Africa reported the detection of a new COVID variant of concern, Omicron, which is more transmissible than even the Delta variant, and has already been found in forty countries around the world.
Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut.
On April 19, 2021, the Director-General of the World Health Organization, Dr. Tedros Ghebreyesus, gave a press conference in which he noted both that the world can bring the COVID-19 pandemic under control within “a matter of months,” and that the number of infections globally has risen each of the last eight weeks, producing 5.2 million new cases. Much of that rise has been driven by the continued emergence of variants.
Johnson & Johnson (NYSE: JNJ) (the Company) today announced the World Health Organization (WHO) and the government of Sierra Leone have begun administering the Company’s Ebola vaccine regimen as part of a WHO early access clinical program aimed at preventing further spread of Ebola in West Africa.
“The African American community, in general, has the highest prevalence of cardiovascular diseases,” says Rachel Bond, M.D., System Director of the Women’s Heart Health Program for Dignity Health in Arizona